On March 19, 2021 Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, reported that it will report financial results for the full year ended December 31, 2020 and provide a business update on March 22, 2021 (Press release, Everest Medicines, MAR 19, 2021, View Source [SID1234576917]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information

A live conference call will be hosted on March 22, 2021 at 9:00 a.m. China Standard Time (March 21, 2021 at 9:00 p.m. Eastern Time). Details are as follows:

Conference ID 7234522#

A replay will be available shortly after the call and can be accessed by visiting the Company’s website at View Source

On March 19, 2021 Centene Corporation (NYSE: CNC) reported a reminder that it will release its 2021 first quarter financial results at approximately 6 a.m. (Eastern Time) on Tuesday, April 27, 2021, and host a conference call afterwards at approximately 8:30 a.m. (Eastern Time) to review the results. Michael F. Neidorff, Chairman, President and Chief Executive Officer, and Jeffrey A. Schwaneke, Executive Vice President and Chief Financial Officer, of Centene Corporation will host the call (Press release, Centene , MAR 19, 2021, View Source [SID1234576916]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 9872494, to expedite caller registration; or via a live, audio webcast on the Company’s website at www.centene.com, under the Investors section.

A webcast replay will be available for on-demand listening shortly after the completion of the call for the next 12 months or until 11:59 p.m. (Eastern Time) on Tuesday, April 26, 2022, at the aforementioned URL. In addition, a digital audio playback will be available until 9 a.m. (Eastern Time) on Tuesday, May 4, 2021, by dialing 1-877-344-7529 in the U.S. and Canada, or +1-412-317-0088 from abroad, and entering access code 10153375.

Later that same day, the company will host its Annual Shareholder Meeting in a virtual format at 11:00 a.m. ET. Information on and shareholder registration for the meeting can be found at: www.virtualshareholdermeeting.com/CNC2021.

On March 19, 2021 Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology, reported that it will present two posters at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021, which will take place virtually from April 10-15 and May 17-21, 2021. The posters will describe insights into exoneural biology discovered via Cygnal’s Exoneural Medicine Platform (EMP).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Title: Neural communication to peripheral tumors regulates cancer cell activity
Number: 1450
Presenter: Monica Thanawala, Ph.D.

Poster Title: Novel mechanisms of Neuropilin-1 inhibition result in improved tumor growth inhibition in vivo
Number: 526
Presenters: Shalini Sethumadhavan, Ph.D., and Eric Zhu, Ph.D.

Both posters will be offered virtually, and Cygnal’s presenters will be available to answer questions via the AACR (Free AACR Whitepaper)’s online system during and after the event. The posters will be available for viewing by registered attendees from April 10 until June 21, 2021.

On March 19, 2021 Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, reported that it has been invited to present at the Benzinga Biotech Small Cap Conference being held virtually on March 24 & 25, 2021 (Press release, Ampio, MAR 19, 2021, View Source [SID1234576914]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

Corporate Overview
Title: Ampio – Business & Pipeline Update
Date: March 24, 2021
Time: 2:00-2:20pm EDT on Track 2
Registration Link: View Source

On March 19, 2021 Isofol Medical AB (publ) ("Isofol"), (Nasdaq First North Premier Growth Market: ISOFOL) reported that the independent Data Safety and Monitoring Board (iDSMB) has recommended continuation of the global Phase III AGENT study with 440 patients, in accordance with the study design for the drug candidate, arfolitixorin (Press release, Isofol Medical, MAR 19, 2021, View Source [SID1234576913]). Isofol expects the top line results for the AGENT study to be available during H1 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The iDSMB recommendation follows a pre-scheduled interim analysis as part of the study design and was initiated when the 330th patient had been treated for 16 weeks and had two tumor evaluations. iDSMB evaluated safety and efficacy (ORR and PFS). The Company remains blinded to the interim analysis results.

"The recommendation from iDSMB is encouraging in many ways; first, it does not require us to recruit additional patients which enables us to keep our current timeline with the goal to submit a New Drug Application to FDA & EMA in H2 2022. Second, it is an additional confirmation that arfolitixorin shows no signs of increased toxicity which in combination with previous efficacy data strengthens our belief in arfolitixorin’s potential. Thirdly, we may be on the market in the US already in 2023", said Ulf Jungnelius, M.D, CEO of Isofol.

Arfolitixorin is evaluated in the AGENT study for the treatment of patients with first-line metastatic colorectal cancer (mCRC). The study is currently being conducted in Australia, Europe, Japan, Canada and the US in more than 90 clinics and includes a total of 440 patients.

This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 18:10 CET on March 19, 2021.

About arfolitixorin

Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global Phase III study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit more patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.